A 2026 gastric cancer strategy report covering global burden, CLDN18.2 and HER2 biology, clinical competition, recent transactions and portfolio positioning.

A 2026 hepatocellular carcinoma strategy report covering liver-disease burden, PD-1 and VEGF biology, clinical competition, recent transactions and R&D positioning.

A 2026 cholangiocarcinoma strategy report covering disease burden, FGFR2 and IDH1 biology, clinical competition, recent licensing and portfolio positioning.

A 2026 esophageal cancer strategy report covering global burden, PD-1 and HER2 biology, clinical competition, transactions and portfolio positioning.

A 2026 clear cell renal cell carcinoma strategy report covering burden, VHL and HIF-2α biology, clinical competition, transactions and portfolio positioning.

Brii Biosciences 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Clover Biopharmaceuticals 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Walvax Biotechnology 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

CanSino Biologics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Sinocelltech 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Lepu Biopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Mabwell 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.